No Data
Changfeng Pharmaceutical (02652) announced its interim results, with revenue reaching RMB 210 million, representing a 2.1% year-on-year increase.
Changfeng Pharmaceutical (02652) announced its interim results for 2026, reporting revenue of RMB 210 million, a year-on-year increase of 2.1%, primarily driven by higher revenue from the CF017 product due to the continued expansion of its customer base and market coverage in the Middle East.
CF PHARMTECH: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2026
HK Stocks in Focus | Changfeng Pharmaceutical (02652) Surges Over 20% Intraday; ICF001 Secures Two Additional Clinical Trial Approvals, Highlighting Significant Advantages of Its Long-Acting Inhaled Prodrug Design
Changfeng Pharmaceutical (02652) surged more than 20% during intraday trading. As of press time, the stock was up 6.14% at HK$16.2, with a turnover of HK$58.31 million.
HK Stock Announcements Spotlight | Leapmotor Releases Interim Results; Profit Attributable to Shareholders Reaches RMB 208 Million, Up 530.97% Year-on-Year
Yunyinggu Technology (03310) announced its interim results, reporting revenue of RMB 318 million, while deepening its presence in the brand AMOLED display driver IC market. HeYu-B (02256) successfully commercialized its core drug, Bejiemai, in the first half of the year, with continued increases in R&D expenditure.
CF PHARMTECH: DATE OF BOARD MEETING
HK Stock Market Midday Review | The three major indices showed mixed performance, with the Hang Seng TECH Index rising 0.3%. Semiconductor stocks advanced, with Hua Hong Hongli surging over 5% and SMIC gaining nearly 4%. Following its earnings release, Te
Internet and technology stocks showed mixed performance, with Tencent down 3.81% and Baidu Group-SW up 2.25%; mobile gaming stocks weakened, with Tencent falling 3.81% and Kingsoft Software dropping 2.92%; non-ferrous metal stocks declined, with Lingbao Gold down 6.78% and Aluminum Corporation of China losing 5.01%;